文献速递瓣膜外科

机械心脏瓣膜置换术后抗凝治疗质量与血栓栓塞及出血风险

Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis.
PubMed 文献 · J Thorac Cardiovasc Surg · 2019-02-27

该丹麦注册研究纳入659例机械心脏瓣膜置换患者,评估术后6个月内维生素K拮抗剂治疗质量(以治疗范围时间TTR≥70%或<70%衡量)与血栓栓塞及出血风险的关系。中位随访6.1年,TTR≥70%组血栓栓塞风险显著低于TTR<70%组(HR 0.44;95%CI 0.22-0.85),而出血风险组间无显著差异(HR 0.63;95%CI 0.36-1.08)。

要点

  • 机械瓣置换术后6个月内TTR<70%与血栓栓塞风险增加相关。
  • TTR≥70%与<70%两组间出血风险无显著差异。

核心结论

  • 机械心脏瓣膜置换术后6个月内TTR<70%与血栓栓塞事件风险增加相关,但与出血风险增加无关。

研究设计与样本

  • 基于丹麦注册数据的回顾性队列研究,纳入1997-2012年间行机械心脏瓣膜置换且有国际标准化比值(INR)数据的659例患者。
  • 评估术后出院至出院后6个月(索引点)的维生素K拮抗剂治疗质量,以TTR≥70%或<70%分组。
  • 从索引点随访至结局事件(血栓栓塞或出血)、死亡或研究结束(2012年12月31日),采用多变量Cox回归估计风险。

主要发现

  • 术后6个月内INR测量中位数为13次(四分位距8-19),TTR中位数为54.9%(四分位距39.0%-72.9%),29.1%的患者TTR≥70%。
  • 中位随访6.1年,TTR≥70%组较TTR<70%组血栓栓塞风险显著降低(HR 0.44;95%CI 0.22-0.85)。
  • 两组出血风险无显著差异(HR 0.63;95%CI 0.36-1.08)。

临床怎么用

  • 机械瓣置换术后应重视抗凝治疗质量,术后6个月内TTR<70%提示血栓栓塞风险增高,需加强抗凝管理以维持TTR≥70%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Oral anticoagulation with vitamin K antagonists is recommended after mechanical heart valve replacement. However, data regarding the association between the quality of vitamin K antagonist treatment and the risk of complications are sparse. METHODS: Patients undergoing mechanical heart valve replacement (1997-2012) with available data on international normalized ratio values were identified in Danish registries. The quality of vitamin K antagonist treatment between discharge after valve replacement and 6 months postdischarge (ie, index) was assessed as time in therapeutic range (TTR) ≥70% or <70% reflecting the percentage of time in therapeutic international normalized ratio interval. Patients were followed from index until occurrence of an outcome of interest (ie, thromboembolism and bleeding), death, or end of study (December 31, 2012), whichever came first. The risk of outcomes according to quality of vitamin K antagonist treatment was estimated with multivariable Cox regression. RESULTS: In total, 659 patients undergoing mechanical heart valve replacement were included in the study. Median number of international normalized ratio measurements in the 6-month period after surgery was 13 (interquartile range, 8-19). Median TTR was 54.9% (interquartile range, 39.0%-72.9%) and 29.1% of patients had a TTR ≥70%. Median follow-up was 6.1 years. The risk of thromboembolism was significantly lower in the group with TTR ≥70% compared with TTR <70% (hazard ratio, 0.44; 95% confidence interval, 0.22-0.85), whereas no significant difference concerning risk of bleeding among groups was found (hazard ratio, 0.63; 95% confidence interval 0.36-1.08). CONCLUSIONS: In patients undergoing mechanical heart valve replacement, TTR <70% in the 6-month period after surgery was associated with an increased risk of thromboembolic events but not bleeding compared with TTR ≥70%.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Havers-Borgersen E, Butt JH, Vinding NE, et al. Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis. J Thorac Cardiovasc Surg. 2019. PMID: 30961980. doi:10.1016/j.jtcvs.2019.02.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。